Grant of Options

16 April 2014

Cyprotex PLC

("Cyprotex" or the "Company")

Grant of Options

Further to the announcement made on 23 January 2014, the Company announces today that John Dootson, Chief Financial Officer of the Company, has been granted 3,333,333 options, all over ordinary shares of 0.1p each as part of the Executive share option scheme.

The vesting of these executive options is on grant, at an exercise price of 5.52 pence per share, and are exercisable only upon change in control of the Company within a ten year period, dependent upon the Company's share price performance and subject to a minimum share price of 12 pence.

For further information:

Notes to Editors:

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo in MI in the US. The Company was established in 1999 and works with more than 800 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com